KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Return on Sales (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Return on Sales for 7 consecutive years, with 0.57% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 1.0% to 0.57% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.56% through Dec 2025, down 3.0% year-over-year, with the annual reading at 0.56% for FY2025, 3.0% down from the prior year.
  • Return on Sales hit 0.57% in Q4 2025 for Royalty Pharma, down from 0.73% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 1.45% in Q2 2021 to a low of 1.08% in Q4 2022.
  • Historically, Return on Sales has averaged 0.5% across 5 years, with a median of 0.47% in 2022.
  • Biggest five-year swings in Return on Sales: plummeted -117bps in 2022 and later surged 228bps in 2023.
  • Year by year, Return on Sales stood at 0.09% in 2021, then tumbled by -1257bps to 1.08% in 2022, then soared by 212bps to 1.2% in 2023, then tumbled by -53bps to 0.56% in 2024, then rose by 2bps to 0.57% in 2025.
  • Business Quant data shows Return on Sales for RPRX at 0.57% in Q4 2025, 0.73% in Q3 2025, and 0.16% in Q2 2025.